NBR Polska Tomasz Klodawski
- Address
- lock Available on a paid plan
NBR Polska Tomasz Klodawski - Diabetic Neuropathy Pain Research Center
NBR Polska Tomasz Klodawski is a clinical research facility specializing in the evaluation of novel therapeutic interventions for complex pain disorders associated with metabolic diseases. The center demonstrates particular expertise in conducting trials focused on diabetic peripheral neuropathy and its associated chronic pain manifestations, contributing to the development of innovative pain management strategies for diabetic patients.
- Chronic pain management in diabetic peripheral neuropathy
- Novel pharmacological interventions for neuropathic pain
- Therapeutic efficacy assessment in metabolic-related pain syndromes
The center's research portfolio reflects a commitment to addressing the challenging intersection of diabetes complications and chronic pain conditions. Through rigorous clinical trial methodology, NBR Polska contributes valuable data on emerging treatments that may significantly improve quality of life for patients suffering from diabetic neuropathic pain, a condition that affects millions of diabetes patients worldwide and remains difficult to treat effectively.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novo Nordisk A/S5trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in NBR Polska Tomasz Klodawski
lock Showing 1 of 7 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A single arm study investigating the glycaemic control and safety of adding semaglutide to insulin icodec in participants with type 2 diabetes qualifying for treatment intensification. | Novo Nordisk A/S | Phase III | Not Recruiting | Jan 2024 | May 2025 |
IMP list
lock Showing 1 of 9 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cagrilintide | 3 | Unknown | 2023-11-07 | 2025-10-31 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.